Industry News
Nicox Reports Positive Results from Whistler Phase 3b Trial of NCX 470 in IOP Reduction

Nicox has announced results from the Whistler Phase 3b exploratory trial, evaluating the intraocular...

read more
Nicox Reports Positive Results from Whistler Phase 3b Trial of NCX 470 in IOP Reduction
May 16, 2025
Bausch + Lomb Launches Zenlens CHROMA HOA Scleral Lens in the U.S.

Bausch + Lomb has officially launched Zenlens CHROMA HOA in the United States—a custom, wavefront-gu...

read more
Bausch + Lomb Launches Zenlens CHROMA HOA Scleral Lens in the U.S.
May 15, 2025
Oral Zervimesine Slows Geographic Atrophy Progression in Phase 2 Dry AMD Trial

Cognition Therapeutics has announced topline results from its Phase 2 Magnify study, evaluating the ...

read more
Oral Zervimesine Slows Geographic Atrophy Progression in Phase 2 Dry AMD Trial
May 14, 2025
Alliance for Healthcare from the Eye Launches to Advance AI-Powered Disease Detection

At the 2025 ARVO Annual Meeting in Salt Lake City, a multi-stakeholder coalition announced the offic...

read more
Alliance for Healthcare from the Eye Launches to Advance AI-Powered Disease Detection
May 14, 2025
Isarna Therapeutics Presents Final Phase 2 Results for ISTH0036 in Wet AMD and DME at ARVO 2025

Isarna Therapeutics presented the final results from its Phase 2 BETTER trial on May 6 at the Associ...

read more
Isarna Therapeutics Presents Final Phase 2 Results for ISTH0036 in Wet AMD and DME at ARVO 2025
May 13, 2025
EyeCool Therapeutics Reports Positive Pilot Study Results for ETX-4143 in Chronic Ocular Surface Pain (COSP)

EyeCool Therapeutics has announced encouraging results from a double-masked, randomized controlled p...

read more
EyeCool Therapeutics Reports Positive Pilot Study Results for ETX-4143 in Chronic Ocular Surface Pain (COSP)
May 12, 2025
Perfuse Therapeutics Reports Positive Phase 1/2a Results for PER-001 Intravitreal Implant in Glaucoma

Perfuse Therapeutics has announced promising 24-week results from its Phase 1/2a clinical trial eval...

read more
Perfuse Therapeutics Reports Positive Phase 1/2a Results for PER-001 Intravitreal Implant in Glaucoma
May 12, 2025
LumiThera’s LIGHTSITE Phase 3B Extension Trial Demonstrates Long-Term Vision Improvement in Dry AMD

LumiThera has announced promising results from its LIGHTSITE 3B extension trial, highlighting contin...

read more
LumiThera’s LIGHTSITE Phase 3B Extension Trial Demonstrates Long-Term Vision Improvement in Dry AMD
May 12, 2025
Topcon Healthcare Launches IDHea to Advance AI and Digital Health Innovation from Ocular Data

Topcon Healthcare has officially launched the Institute of Digital Health (IDHea), a next-generation...

read more
Topcon Healthcare Launches IDHea to Advance AI and Digital Health Innovation from Ocular Data
May 09, 2025
Alkeus Pharmaceuticals Presents Positive 24-Month Phase 2 Data for Gildeuretinol in GA at ARVO 2025

Alkeus Pharmaceuticals, Inc. presented additional 24-month results from its Phase 2 SAGA clinical tr...

read more
Alkeus Pharmaceuticals Presents Positive 24-Month Phase 2 Data for Gildeuretinol in GA at ARVO 2025
May 09, 2025
More